News Related to Hodgkin Lymphoma

Related coverage linked through entity extraction aliases.

FDA Approves Nivolumab for Pediatric Hodgkin Lymphoma, Clears Two Investigational Drugs for Trials

Apr 03, 2026

The FDA has approved nivolumab with chemotherapy for pediatric and adult Hodgkin lymphoma patients aged 12+, based on clinical trial data showing improved survival. Separately, the agency cleared investigational new drug applications for FG001 for brain cancer surgery visualization and FRF-001 gene therapy for FOXG1 syndrome, allowing both to proceed to clinical trials.

Cancer Treatment Timing and Long-Term Effects Under Study

Mar 06, 2026

New research examines both the long-term biological aging effects of childhood cancer treatments and proposes alternative treatment sequencing strategies to prevent tumor resistance and improve cure rates.

FDA Approves KEYTRUDA for Platinum-Resistant Ovarian Cancer

Feb 15, 2026

The FDA approved KEYTRUDA and its subcutaneous QLEX formulation for platinum-resistant ovarian cancer, marking the first PD-1 inhibitor cleared for this patient population based on Phase 3 results.